Editor-in-Chief, Robert Amdur, MD, explains the group of six papers on radiopharmaceutical therapy published in the July/August issue of Practical Radiation Oncology. These papers summarize the information clinicians need to know to direct radiopharmaceutical therapy in their clinic. Two papers explain background information and four focus on patient selection and the details of administration when using Lutetium-177 DOTATATE for neuroendocrine cancer, and Lutetium-177 PSMA or Radium- 223 for prostate cancer.
